Kornimate/medical-research-clean huggingface dataset:
association of probable bruxism with periodontal status

Conditions: Bruxism

Summary: this cross-sectional study was conducted to assess i) the prevalence of probable bruxism ii) the association between probable bruxism and periodontal status.the age, gender, education level, tooth loss, presence of probable bruxism and periodontal status of patients were evaluated. periodontal statuses of the participants were defined according to the american association of periodontology/european federation of periodontology, 2017 consensus and assessment of probable bruxism was performed according to the 2018 consensus report on the assessment of bruxism.

this cross-sectional study was conducted to assess i) the prevalence of probable bruxism ii) the association between probable bruxism and periodontal status dental examination, all participants completed a standardized questionnaire. sociodemographic findings comprised age, gender and educational level. periodontal statuses of the participants were defined according to the american association of periodontology/european federation of periodontology, 2017 consensus. participants were diagnosed with periodontitis if interdental clinical attachment loss (al) was detected at ≥2 non-adjacent teeth, or buccal or oral al was ≥3 mm with probing depth \>3 mm was detected at ≥2 teeth. 12 in addition number of missing teeth is recorded.assessment of probable bruxism was performed according to the 2018 consensus report on the assessment of bruxism.presence of masticatory muscle hypertrophy, temporomandibular joint pain, indentations on the tongue or lip and/or a linea alba on the inner cheek, damage to the dental hard tissues (eg, cracked teeth), mechanical wear of the teeth (ie, attrition), repetive failures of restorative work/prosthodontics constructions were examined in clinical evaluation.

Eligibility criteria:
inclusion criteria: * patients with 18 years and older exclusion criteria: * age under 18 years, * edentulous patients, * not interested to participate in this study.
anterior deprogrammers for reducing pain and masticatory muscles tension

Conditions: Temporomandibular Disorders

Summary: the study will be conducted in four groups of 20 patients in age of 20-30 years with complete dentition or single tooth loss in lateral regions, with masticatory muscle pain in the history or during examination and overuse and/or chronic tensing of the masticatory muscles. patients will be randomly assigned to the groups. each person will be measured twice before and after use of selected anterior deprogrammer. the following assessment tools will be applied: * surface electromyography of masseter and temporal muscles, * intraoral pin-supported registration to draw a gothic arch. measurements will be made before and after intervention to assess the effect of anterior deprogrammer application on the tone of the selected masticatory muscles and condyles position in mandibular fossa. the first group (control) will be counsel with an explanation of the pathomechanism of masticatory muscles pain and preventive principles. in the second group, the sliding guide will be used for a period of 12-15 minutes, in the third dawson b-splint for 7 days, and in the fourth kois deprogrammer for 14 days. devices in group 3 and 4 will be used by patients for 24 hours a day, with breaks for oral hygiene procedures and eating/drinking. the aim of the study is to evaluate the effectiveness of selected anterior deprogrammers.


Eligibility criteria:
inclusion criteria: * age 20-30 years old * complete dentition or single tooth loss in the lateral regions * no severe systemic diseases * masticatory muscle pain in the history or during examination * increased masticatory muscles tension

Keywords: anterior deprogrammer muscle pain centric relation
endoprosthetic replacement for pathological fractures of the hip: a 35-year update

Conditions: Hip Fractures; Hip Fracture Pathologic; Pathological Fracture; Pathological Fracture of Hip

Summary: this study will be based on a retrospective review of patients who received endoprosthetic reconstruction for pathologic fracture of the proximal femur. the objectives would be two-fold: (1) to compare rates ofambulation, pain, and survival to the historic cohort and (2) to identify predictors of ambulation in the current population.


Eligibility criteria:
inclusion criteria: * participants have received endoprosthetic reconstruction for pathologic fracture of the proximal femur exclusion criteria: * participants with fractures greater than 3mm from the lesser trochanter * participants without histopathologic confirmation of tumor

Keywords: hip fractures pathological hip fractures hip fracture parthologic pathological fracture of hip 16-1122 memorial sloan kettering cancer center
4d medical x-ray velocimetry for bronchoscopic lung volume reduction targeting

Conditions: Copd; Emphysema; Hyperinflation

Summary: this study will investigate the utility of 4d medical's x-ray velocimetry (xv) imaging analysis software for the detection of hyperinflation, and compare endobronchial valve placement outcomes with predictive indices obtained utilizing this technique.


Eligibility criteria:
inclusion: * ct chest and pfts within the last two years * age over 18 * copd with emphysema * global initiative for chronic obstructive lung disease (gold) 3 - 4 classification or modified medical research council (mmrc) score of 2 or greater. exclusion criteria: * pregnancy * presence of an additional pulmonary disease beyond copd * inability to raise arms above 90 degrees as required for fluoroscopy
palmoplantar pustulosis and generalized pustular psoriasis: a national population-based analysis of prevalence

Conditions: Palmoplantar Pustulosis; Generalized Pustular Psoriasis

Summary: this study plans to calculate the prevalence and incidence of palmoplantar pustulosis and generalized pustular psoriasis based on the national medical insurance data and analyze the composition characteristics and some clinical features of patients, through taking into account of the research status of palmoplantar pustulosis and generalized pustular psoriasis and the characteristics of medical insurance data.


Eligibility criteria:
inclusion criteria: * the insured population of the national urban employee basic medical insurance and the urban resident basic medical insurance from january 1, 2012, to december 31, 2016 (60 months) (the denominator) * the patients have been diagnosed with palmoplantar pustulosis or generalized pustular psoriasis (including disease name, english abbreviation and icd code) * both outpatient and inpatient patients are included exclusion criteria: * the individuals whose information is only contained in the reimbursement settlement database but not in the insurance coverage database will be considered as invalid reimbursement individuals and be excluded from the study (the denominator) * the patients have been diagnosed with non-ppp and -gpp diseases, such as pustular psoriasis in palm and toe, pustular arthritis osteitis and sapho syndrome

Keywords: generalized pustular psoriasis palmoplantar pustulosis urban employee basic medical insurance (uebmi) data prevalence incidence
lenalidomide, rituximab, gemcitabine, oxaliplatin and dexamethasone in relapse and refractory dlbcl

Conditions: Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory

Summary: previous study showed that lenalidomide or r-gdp could achieve response in relapse and refractory dlbcl.the investigators therefore design this phase i study to investigate the safety and efficacy of r2-god in relapsed diffuse large-cell lymphoma.


Eligibility criteria:
inclusion criteria: * age 18-65 years old; * ecog ps 0- 2; * histologically confirmed diffuse large b cell lymphoma（with exception of primary mediastinal large b cell lymphoma、primary central nervous system lymphoma、hiv-related lymphoma),relapse or refractory,defined as: * relapse after standard first-line immunochemotherapy( r-chop or r-chop like) * sd as best response after 4 cycles or pd after 2 cycles of first-line immunochemotherapy; * a measurable or evaluable disease at the time of enrollment(diameter ≥ 1.5cm）； * eligible for subsequent autologous stem cell transplantation； * female subjects in childbearing age, their serum or urine pregnancy test must be negative. all patients must agree to take effective contraceptive measures during the trial measures * expected survival ≥ 12 weeks； * understand and voluntarily sign an informed consent form, able to adhere to the study visit schedule and other protocol requirements exclusion criteria: * women who are pregnant or lactating. patients have breeding intent in 12 months or cannot take effective contraceptive measures during the trial measures； * uncontrollable active infection within four week. prophylactic antibiotic, antiviral and antifungal treatment is permissible. active hepatitis b or hepatitis c virus infection, as well as acquired, congenital immune deficiency diseases, including but not limited to hiv-infected persons； * used of systemic anti-tumor treatment within four weeks； * cns or meningeal involvement; * poor hepatic and/or renal function, defined as total bilirubin, alt, ast, cr more than two fold of upper normal level,ccr\< 50 ml/min unless these abnormalities were related to the lymphoma; * poor bone-marrow reserve, defined as neutrophil count less than 1.5×10⁹/l or platelet count less than 75×10⁹/l, unless caused by bone marrow infiltration; * new york heart association class iii or iv cardiac failure; or ejection fraction less than 50%;or history of following disease in past 6 months: acute coronary syndrome、acute heart failure、severe ventricular arrhythmia； * known sensitivity or allergy to investigational product; * major surgery within three weeks; * presence of grade iii nervous toxicity within past two weeks; * active and severe infectious diseases; * history of dvt or pe within past 12 months； * any potential drug abuse, medical, psychological or social conditions which may disturb this investigation and assessment; * in any conditions which investigator considered ineligible for this study.

Keywords: lenalidomide r-god dlbcl
non-interventional study (nis) on sodium-glucose co-transporter-2 inhibitors (sglt2i) use in france

Conditions: Diabetes Mellitus, Type 2

Summary: the primary objective of this study are: - describe the characteristics of all patients initiating sodium-glucose co-transporter-2 inhibitors (sglt2i) and the modalities of prescriptions of these two drugs and the concomitant treatments. the secondary objectives are: * assess the occurrence of atheromatous cardiovascular events (unstable angina, fatal and non-fatal myocardial infarction (mi), transient ischemic attack (tia), fatal and non-fatal stroke), deaths from all causes, hospitalization for heart failure and hospitalization for end-stage renal disease as main and related diagnoses during the exposure to the studied treatment * assess the occurrence of the main safety events (ketoacidosis, lower limb amputation and fournier's gangrene) during the exposure to the studied treatment


Eligibility criteria:
inclusion criteria: * population includes all patients initiating a treatment with sglt2i between april 1, 2020, and december 31, 2024. exclusion criteria: * none
study to assess batoclimab in participants with active thyroid eye disease

Conditions: Thyroid Eye Disease

Summary: to evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (sc) once a week (qw) for 12 weeks followed by 340 mg sc qw for 12 weeks versus placebo on proptosis responder rate at week 24.


Eligibility criteria:
inclusion criteria: 1. are ≥18 years of age at screening. 2. have a clinical diagnosis of ted associated with active, moderate to severe ted with the following at screening and visit 0: * a cas ≥ 4 in either eye, and * clinical evidence of worsened proptosis with: * proptosis ≥ 18 mm and/or * proptosis ≥ 3 mm increase from participant's baseline (prior to diagnosis of ted), as estimated by the investigator/assessor 3. have moderate to severe active ted, as defined by european group on graves' orbitopathy (eugogo) guidelines. 4. have onset of active ted within 12 months prior to screening. 5. have documented evidence of detectable anti-tshr-ab at screening. 6. are not expected to require immediate surgical intervention and are not planning corrective surgery/irradiation or medical therapy for ted during the course of the study. 7. are euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism. additional inclusion criteria are defined in the protocol. exclusion criteria: 1. have decreased best corrected visual acuity due to optic neuropathy. 2. have at least a 2-point decrease in cas or ≥2 mm decrease in proptosis between screening and baseline assessments in either eye. 3. have used any steroid (intravenous or oral) for the treatment of ted or other conditions within 4 weeks prior to screening. 4. have used any steroid (intravenous or oral) with a cumulative dose equivalent to ≥ 1 g of methylprednisolone for the treatment of ted. 5. have known autoimmune disease other than ted, that, in the opinion of the investigator, would interfere with the course and conduct of the study. 6. had previous orbital irradiation or surgery for ted. additional exclusion criteria are defined in the protocol.

Keywords: batoclimab thyroid eye disease imvt-1401 monoclonal antibody autoimmune disorders graves' ophthalmopathy graves' orbitopathy
effect of antibiotics on penile microbiome and hiv susceptibility study in ugandan men

Conditions: Foreskin HIV Susceptibility

Summary: this pilot study will assess the impact of four antimicrobial products (3 topical, one systemic) on the foreskin microbiome and hiv susceptibility of foreskin-derived cd4+ t cells. participants will include hiv-uninfected ugandan men presenting for elective male circumcision to reduce their hiv risk.

rationale: the foreskin is the site of most hiv acquisition in uncircumcised heterosexual men, and male circumcision (mc) reduces hiv risk by almost 60%. however, cultural and practical barriers have led to suboptimal uptake. foreskin inflammation, defined by elevated levels of pro-inflammatory cytokines in the prepuce, is a key determinant of hiv acquisition risk in uncircumcised men, and anaerobic bacteria within the foreskin microbiome may be an important cause of this inflammation. objectives: a pilot in vivo - in vitro clinical study of four potential interventions to reduce hiv susceptibility in the foreskin by altering the microbiome. the study is a collaboration between the university of toronto, iavi-uvri, and the entebbe general hospital. we will recruit 125 men presenting for elective mc, along with regular female sexual partners (if applicable). participants will be randomized (n=25 per group) to immediate mc, or to one of four intervention arms: twice-daily application of topical metronidazole 0.75%; twice-daily application of topical clindamycin 2%; twice daily application of hydrogen peroxide 1%; or oral tinidazole 2g once a day for two days. swabs for immune and microbiome studies will be collected before and after product. after 4 weeks the mc procedure will be performed; foreskin cd4+ t cell susceptibility to hiv will be quantified using a flow cytometry-based pseudovirus assay, and tissue immunohistochemistry performed. the primary and secondary endpoints are outlined below. a secondary study will assess the impact of penile topical antibiotic application on immunology and the microbiome in the genital tract of female sexual partners. outcomes: this in vivo - in vitro clinical trial will define the causal role of the penile microbiome in hiv susceptibility, and will assess potential strategies to take forward into hiv efficacy trials in uncircumcised heterosexual men.

Eligibility criteria:
enrollment criteria include: 1. aged 18 years or older 2. biological male 3. uncircumcised 4. hiv seronegative 5. willing to comply with the requirements of the protocol 6. no current sexually transmitted infection (n. gonorrhoeae or c. trachomatis) 7. no clinically relevant genital symptoms / signs
a study to evaluate the pharmacokinetic drug-drug interactions between vx-548, midazolam, and digoxin

Conditions: Pain

Summary: the purpose of this study is to evaluate the pharmacokinetics of midazolam and digoxin in the absence and presence of vx-548.

this clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (that is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(a) of the public health service act and 42 cfr 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the public health service act or 42 cfr 11.24 and 11.44.).

Eligibility criteria:
key inclusion criteria: * body mass index (bmi) of 18.0 to 32.0 kilogram per meter square (kg/m\^2) * a total body weight greater than (\>) 50 kilogram (kg) * females of non-childbearing potential key exclusion criteria: * history of febrile illness or other acute illness that has not fully resolved within 5 days before the first dose of study drug * any condition possibly affecting drug absorption * history of cardiovascular disease, cardiac dysrhythmias or central nervous system disease * hypersensitivity to midazolam, other benzodiazepines, or digoxin other protocol defined inclusion/exclusion criteria may apply.
walking for health: an intervention to increase physical activity and reduce sedentary behaviour in people with smi

Conditions: Mental Illness; Schizophrenia; Bipolar Disorder; Major Depression; Psychosis

Summary: people who have a severe mental illness can have poorer physical health and higher mortality rates than the general population. their medications combined with low levels of physical activity and increased sedentary behaviour can general population and may help people with severe mental illness to be more active. a previous feasibility study has been conducted in the uk in a large city with positive findings. the current study will be conducted in rural settings in northern ireland and republic of ireland. the intervention will last 13 weeks. people with severe mental illness will be randomly assigned into one of two groups. both groups will get information on the benefits of physical activity. in addition, one group will be shown how to use a step counter to measure their steps, be invited to a weekly group walk, and meet their coach every 2 weeks contribute to this. walking is a good way to increase physical activity in the to see how they are getting on and to support them. the research team are interested in finding out how willing clinicians are to recruit people into the study, how willing people are to take part, do people then stick with the programme, and if not the reasons for people dropping out. qualitative findings will explore whether participants feel they benefited from and enjoyed the programme. findings will be used to investigate the feasibility to conduct a larger trial like this in the future.


Eligibility criteria:
inclusion criteria: * inactive adults (male or female; aged ≥18 years) * diagnosis of any smi (schizophrenia, psychosis, bipolar disorder and major depression). exclusion criteria: * significant movement impairment * identified as 'active' using the gppaq screening tool * unable to understand english or lack comprehension to understand the purpose of the study and given written informed consent.
optical detection infiltration/extravasation in neonates (odine)

Conditions: Extravasation Injury; Infant, Premature, Diseases

Summary: peripheral intravenous (piv) therapy is one of the most common invasive procedures performed in hospitals. piv failures often occur when fluids leak out of the vein into surrounding tissue. this failure is usually called infiltration if the leakage involves non-vesicant solutions or extravasation in case of vesicant solutions. in this clinical study both infiltration and extravasation events are indicated by the term "infiltration". neonatal intensive care unit patients are an high-risk population for infiltration due to their intrinsic characteristic: poor and fragile vein asset, frequent and uncontrolled movements, need for prolonged intravenous drug and fluid administration. current nursing practice involves regular piv site assessments for continuous infusions; particular attention is payed to the identification of swelling, pain, redness, warmth, or coolness. as infiltration represents a leading cause of iatrogenic injury, an early identification, an early identification can minimize its consequences. the ivwatch model 400 is a device that assists medical professionals in monitoring patients for piv infiltrations using an optical sensor. this device received fda clearance and european conformity mark for use in the adult and pediatric age groups. ivwatch enhanced the model 400 to support a new disposable electronic sensor (smarttouch sensor). in this study, the smarttouch sensor will be tested in a neonatal population in a nicu setting. the new sensor design includes optical components in the sensor package, similar to a typical pulse oximeter. primary study objective is to investigate whether the ivwatch smarttouch sensor may be helpful in early identification of any kind of infiltration, if compared with our current standards of care.


Eligibility criteria:
inclusion criteria: * term and pre-term infants; * birth weight \> 1.5 kg; * need for continuous iv therapy with an expected duration \> 24 hours. exclusion criteria: * birth weight \</= 1.5 kg; * non continuous iv therapy; * iv therapy expected duration \</= 24 hours; * skin disorders.
myopia progression and the effect of 7-methylxanthine

Conditions: Myopia

Summary: 7-methylxanthine has been shown to increase the concentration and thickness of collagen fibrils in rabbit sclera. deficient collagen in the sclera may be the cause of progression of childhood myopia. the study hypothesis is that treatment with 7-methylxanthine will stabilize the sclera and prevent further progression of myopia.

participants are given tablets of 7-methylxanthine 400 mg per day or placebo tablets for 12 months. axial length, cycloplegic refraction and corneal curvature is measured, as well as weight, height, blood pressure and heart rate. the participants are interviewed about possible cns, gastrointestinal, or cardiopulmonal side effects.

Eligibility criteria:
inclusion criteria: children in the age 8-13 years with myopia and an axial growth rate of 0.15 mm or more per year. - exclusion criteria: severe general ailment (for example diabetes, epilepsy, psychiatric disease) eye diseases (for example cataract, keratoconus, chronic iritis, glaucoma) -